Its a small-molecule NNMT inhibitor, blocking an enzyme (nicotinamide N-methyltransferase) involved in fat cell metabolism
The complex travels through the small intestine until it reaches the terminal ileum, where specialised receptors called cubam (a complex of cubilin and amnionless proteins) recognise and facilitate the uptake of the B12-IF complex into enterocytes (intestinal cells)
Potential for Synergistic Use When used together, TB 500 and BPC 157 may enhance each others healing effects, providing a comprehensive approach to injury recovery

Commonly Reported Research Observations Injection-site redness or irritation Temporary swelling or warmth sensation at the administration site Burning or stinging during administration Temporary skin sensitivity or irritation Mild headaches Temporary fatigue or tiredness Mild nausea Temporary itching or flushing sensations Temporary blue-tinted discoloration beneath the administration area in some research settings Copper-Related Research Considerations Because GHK-Cu is a copper-binding peptide, some research protocols may monitor for: Copper- and zinc-balance variability Increased sensitivity in higher-frequency protocols Temporary skin-related response variability Individual differences in antioxidant-response pathways Research involving prolonged or higher-frequency protocols commonly investigates the inclusion of: Zinc supplementation Vitamin C supplementation alongside GHK-Curelated research models
Why does PDA matter for surgery
Studies demonstrate that NNMT inhibition "enhances fasting blood glucose levels, glucose tolerance, and insulin sensitivity" while reducing triglycerides and decreasing lipid deposition